Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024

BIO-TECHNE Corp

Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.
McManus receives $550K base salary, 90% target cash incentive, $950K RSU grant, and other equity awards.
McManus succeeds Kim Kelderman, who will become Bio-Techne CEO effective Feb 1, 2024.
Employment agreement has three-year initial term; severance equal to one year base salary plus prorated incentive.
McManus previously led Bio-Techne's Molecular Diagnostics Division after Asuragen acquisition.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Matthew McManus

President – Diagnostics and Genomics Segment

TECH · BIO-TECHNE Corp

Effective: 2024-01-08
Filed: January 8, 2024, 6:59 PM ET

On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Matthew McManus was appointed as President – Diagnostics and Genomics Segment at BIO-TECHNE Corp.

Action: appointed
Role: President – Diagnostics and Genomics Segment

Exact text from the filing

On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.

View on SEC.gov

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-000125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.